fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Nystatin

All products: not a benefit

Mycostatin · DIN 00029556 · 100000U/g · Oint

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2002 · checked November 17, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Mycostatin · DIN 00029556 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-07-30 · brand MYCOSTATIN ONT 100000IU/GM · ATC D01AA01 NYSTATIN · form Ointment · route Topical · ingredients NYSTATIN 100000 UNIT/G · company Squibb canada inc., division of bristol-myers squibb canada inc. · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Mycostatin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00029556)

Source record
DIN 00029556: Mycostatin Raw flags: notABenefit=Y, sec3=Y Item: 840408005; group id 823; item number 2006; lccId None; manufacturer id BQU Source form: Oint; strength: 100000U/g Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00029556 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=832 Therapeutic Notes (formulary) Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.
Interchangeable products
Ratio-Nystatin · DIN 02194228 · $0.1277
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00029556
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2002 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D01A): coverage varies; not interchangeable

  • Clotrimazole (Clotrimaderm): general benefit, not a benefit
  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Terbinafine (Lamisil): general benefit
  • Ciclopirox (Penlac): not a benefit
  • Betamethasone dipropionate + clotrimazole (Lotriderm Cream): not a benefit
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

FLUCONAZOLE

· 9 products · Limited Use, codes 235 · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no link

Other review policies

For Mycostatin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026